Ask Us

If you would like to contact Genzyme with questions about Gaucher disease or Cerezyme, please fill in the fields below and click "submit." The information you provide will be maintained in accordance with our privacy policy.

The Medical Information group will reply within 5 business days.

Unfortunately, Genzyme cannot accept medical questions via the web that contain patients' personal or confidential medical information. Questions requiring background description of medical conditions should be directed to Genzyme via fax 800-737-3642 0r 617-591-7178 or phone 800-745-4447 or 617-768-9000. By clicking the 'submit' button, I hereby confirm that the question(s) I am submitting to Genzyme do not contain any confidential medical information pertaining to either myself or my patients.

* All marked fields are required.

Please correct the items highlighted in red.

* First Name:* Last Name:* Street Address:Street Address 2:* City:* State: Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming * Zip Code:

* Daytime Telephone: - -

Fax: - -

Email Address:Confirm Email Address:* Question or Comment:

* Enter the code shown above

* Enter the words you hear

You entered the code wrong. Please try again.

  

Please correct the items highlighted in red.

Submit

Indication & Usage

Cerezyme^® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

1. anemia
2. thrombocytopenia
3. bone disease
4. hepatomegaly or splenomegaly

Important Safety Information

Approximately 15% of patients have developed IgG antibodies, and these patients have a higher risk of hypersensitivity reaction. Therefore periodic monitoring is suggested; caution should be exercised in patients with antibodies or prior symptoms of hypersensitivity. Symptoms suggestive of hypersensitivity occurred in 6.6% of patients, and include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension.

Reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of injection.

To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch

Please see Full Prescribing Information (PDF).